ConductScience.org, home

Paper39697210

The current socioeconomic and regulatory landscape of immune effector cell therapies.

Sainatham C and 8 others. Front Med (Lausanne), 2024. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. The current socioeconomic and regulatory landscape of immune effector cell therapies. Papers, record 39697210. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39697210

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The current socioeconomic and regulatory landscape of immune effector cell therapies.
PubMed
Journal
Front Med (Lausanne)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
3.24, provisional
iCite
Revised in PubMed
2026-09-23
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sainatham CChiranjeevi
2Yadav DDevvrat
3Dilli Babu AAravind
4Tallapalli JRJayanth Reddy
5Kanagala SGSai Gautham
6Filippov EEvgenii
7Murillo Chavez FFranco
8Ahmed NNausheen
9Lutfi FForat

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References184

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13252793341BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.J Immunother Cancer2020https://conductscience.org/library/papers/32527933PubMed
235442451Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.JAMA Netw Open2022https://conductscience.org/library/papers/35442451PubMed
338763416TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians.Transplant Cell Ther2024https://conductscience.org/library/papers/38763416PubMed
429385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
531031762Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.Front Immunol2019https://conductscience.org/library/papers/31031762PubMed
6259390634-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.Nat Med2015https://conductscience.org/library/papers/25939063PubMed
737047272CAR T Cell Therapy: A Versatile Living Drug.Int J Mol Sci2023https://conductscience.org/library/papers/37047272PubMed
822700725Economics of hematopoietic cell transplantation.Blood2012https://conductscience.org/library/papers/22700725PubMed
929491696The 21st Century Cures Act: FDA Implementation One Year Later: Some Action, Some Results, Some Questions.P T2018https://conductscience.org/library/papers/29491696PubMed
1016728277Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.Exp Hematol2006https://conductscience.org/library/papers/16728277PubMed
1135523472Bench at Bedside Models Facilitate CAR-T Cell Supply Chain.Transplant Cell Ther2022https://conductscience.org/library/papers/35523472PubMed
1228366766Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers.Mol Ther2017https://conductscience.org/library/papers/28366766PubMed
1328061985Multiple myeloma epidemiology and survival: A unique malignancy.Semin Oncol2016https://conductscience.org/library/papers/28061985PubMed
1434279805Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.Adv Ther2021https://conductscience.org/library/papers/34279805PubMed
1538077331Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations.Front Immunol2023https://conductscience.org/library/papers/38077331PubMed
1637754534Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update.Curr Oncol2023https://conductscience.org/library/papers/37754534PubMed
1730884772Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.Int J Mol Sci2019https://conductscience.org/library/papers/30884772PubMed
1833312759Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial.Oncoimmunology2020https://conductscience.org/library/papers/33312759PubMed
1934904798Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.N Engl J Med2022https://conductscience.org/library/papers/34904798PubMed
2029451276Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.Drugs Today (Barc)2017https://conductscience.org/library/papers/29451276PubMed

See all 184 referencesDownload CSV of references

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
42935367An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres.Med J Aust2026https://conductscience.org/library/papers/42935367PubMed
42812538The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatment.Front Mol Med2026https://conductscience.org/library/papers/42812538PubMed
42733623A Literature Review of Immunotherapeutics in the Management of Adult B-Cell Acute Lymphoblastic Leukemia.Blood Lymphat Cancer2026https://conductscience.org/library/papers/42733623PubMed
42512343Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma.Cancers (Basel)2026https://conductscience.org/library/papers/42512343PubMed
42321853Novel approaches to modulate CAR-T cell function by targeting the tumor microenvironment in ovarian cancer.J Ovarian Res2026https://conductscience.org/library/papers/42321853PubMed
42240912Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions.Mol Biol Rep2026https://conductscience.org/library/papers/42240912PubMed
42098290A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases.NPJ Precis Oncol2026https://conductscience.org/library/papers/42098290PubMed
41993194CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead.Front Immunol2026https://conductscience.org/library/papers/41993194PubMed
41976395Integrating Artificial Intelligence, Circulating Tumor DNA, and Real-World Evidence to Optimize Hematologic Clinical Trials: Toward Adaptive and Learning Trial Designs.Cancers (Basel)2026https://conductscience.org/library/papers/41976395PubMed
41958651Targeting IL-12 for pancreatic cancer immunotherapy: advances in delivery strategies and clinical translation.Front Immunol2026https://conductscience.org/library/papers/41958651PubMed
41928252In vivo CAR-T therapy: from molecular design to precision delivery.J Nanobiotechnology2026https://conductscience.org/library/papers/41928252PubMed
41900826The 3D Collagen Network as a Determinant of Tumor Progression and Drug Delivery Efficiency in Breast Cancer.Pharmaceutics2026https://conductscience.org/library/papers/41900826PubMed
41832248Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1.Discov Oncol2026https://conductscience.org/library/papers/41832248PubMed
41718362Activated Lymphocyte-Based Immunotherapy Plus Tomotherapy in an Older Patient with Stage III Lung Cancer: A Case Report.Geriatrics (Basel)2026https://conductscience.org/library/papers/41718362PubMed
41559435CAR-engineered cell therapies: current understandings and future perspectives.Mol Biomed2026https://conductscience.org/library/papers/41559435PubMed
41089193Exploring the interactions of integrins and CEACAM6 (Review).Exp Ther Med2025https://conductscience.org/library/papers/41089193PubMed
41012519Formulation of Recombinant Therapeutic Proteins: Technological Innovation, Regulations, and Evolution Towards Buffer-Free Formulations.Pharmaceutics2025https://conductscience.org/library/papers/41012519PubMed
40890617Taming renal inflammation: signaling pathways and therapeutic advances in lupus nephritis.BMC Nephrol2025https://conductscience.org/library/papers/40890617PubMed
40616240Experience and Needs of Immunotherapy for Lung Cancer Patients: A Meta-Synthesis of Qualitative Studies.Psychooncology2025https://conductscience.org/library/papers/40616240PubMed
40603629CAR T cell therapy for children with rheumatic disease: the time is now.Nat Rev Rheumatol2025https://conductscience.org/library/papers/40603629PubMed

See all 22 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CARS1833PubTator's text mininghttps://conductscience.org/library/genes/833NCBI Gene
HLA-C3107PubTator's text mininghttps://conductscience.org/library/genes/3107NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene
TRBV20OR9-26962PubTator's text mininghttps://conductscience.org/library/genes/6962NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39697210

GET https://conductscience.org/api/papers/v1/39697210/references?page=2